CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES
SJIF Impact Factor: 7.187
https://doi.org/10.5281/zenodo.18788680

Available online at: http://www.iajps.com Review Article

PRECLINICAL ROLE OF CANNABINOID CB2 RECEPTOR MODULATORS IN THE MANAGEMENT OF NEUROPATHIC PAIN

Vinjavarapu.L.Anusha*,V.Pardha Saradhi[1], O.Roddick Meitei[1], B.Mounika rani[1], M.Sirisha[1], K.Jahnavi[1], L.Samathasri[1], K.Bhuvananagasai sri[1], S.Madhu latha[1], D.Madhu latha[1], B.Swarna[1], P.Poojitha[1], P.Lakshmi narayana[1], P.Anilkumar[1]

*Associate Professor, Department of Pharmacology, Sims College of Pharmacy, Mangaldasnagar, Guntur, Andhra Pradesh, 522001

[1]Students of Pharmacy, Sims College of Pharmacy, Mangaldasnagar, Guntur, Andhra Pradesh,522001

Abstract

Neuropathic pain, caused by nerve injury or dysfunction, is a major clinical problem because of the lack of effective treatments and side effects of available therapies. The cannabinoid CB2 receptor, which is highly expressed in immune and peripheral tissues, has an anti-inflammatory and analgesic role. Preclinical evidence emerging illustrates that CB2 receptor modulators, particularly selective agonists, inhibit neuropathic pain behaviors by inhibiting neuroinflammation and nociceptive neuron sensitization with no CNS side effects typical of CB1 receptor activation. This review compiles current progress in CB2 receptor-targeted neuropathic pain pharmacotherapy, detailing mechanisms, efficacy, and prospective therapeutic implications. Neuropathic pain, typically secondary to nerve injury or disease, continues to be a significant clinical problem because of the insufficiency of relief by existing treatments and the weight of their side effects. The cannabinoid CB2 receptor, largely expressed in peripheral tissues and immune cells, becomes significantly increased in both peripheral and central nervous system elements under neuropathic pain conditions. Activation of this receptor by CB2-selective agonists preferentially inhibits sensitized nociceptive neurons and decreases the behavioral expression of pain like mechanical allodynia and thermal hyperalgesia in several animal models, including those involving traumatic nerve injury and chemotherapeutic agents. Mechanistically, modulation of the CB2 receptor blocks neuroinflammatorysignaling, as illustrated by reduced microglial activation and decreased release of pro-inflammatory cytokines, leading to normalization of neuronal excitability and pain thresholds. In contrast to CB1 agonists, CB2-selective compounds are not associated with central nervous system side effects, including psychoactivity and addiction, making them potential candidates for more secure pain therapy. Collectively, preclinical studies emphasize CB2 receptor agonists as significant therapeutic drugs by dampening both peripheral and central sensitization mechanisms in neuropathic pain, which demands further exploration for clinical application.

Keywords: *Neuropathicpain,CB2agonists, Neuroinflammation, Nociception, hyperalgesia*

Corresponding author:
Vinjavarapu.L.Anusha,
Associate Professor,
Department of Pharmacology,
Sims College of Pharmacy, Mangaldasnagar, Guntur,
Andhra Pradesh, 522001
Mail id- anushapharmacy90@gmail.com

QR CODE

Please cite this article in press *Vinjavarapu.L.Anusha* ***et al., PRECLINICAL ROLE OF CANNABINOID CB2 RECEPTOR MODULATORS IN THE MANAGEMENT OF NEUROPATHIC PAIN., Indo Am. J. P. Sci, 2026; 13(02).***

1.INTRODUCTION:

CB2 receptors have proved to be a potential therapeutic target for Cannabinoid treatment of neuropathic pain, a condition involving complex pain from nerve damage or disease and having chronic pain, hypersensitivity, and few available treatment options. Two main receptors, CB1 and CB2, form the endocannabinoid system, which plays a key role in pain modulation. While CB1 receptors are found in high density in the central nervous system and mediate the psychotropic effects of cannabinoids, CB2 receptors occur predominantly in peripheral tissues and immune cells and do not produce psychoactive side effects upon activation. Recent research has established that CB2 receptors get upregulated within peripheral nerves as well as central nervous system areas, such as the spinal cord and dorsal root ganglia, during pathological pain conditions like neuropathy. Stimulation of these receptors results in attenuated neuroinflammation and lowered release of pro-inflammatory cytokines from glial cells and immune cells, leading to inhibition of nociceptive transmission and nociceptive behaviors. Unlike traditional pain drugs, which are not always effective or have undesirable side effects, CB2 receptor modulators represent an alternative to approach neuroimmune pathways associated with pain syndromes. The therapeutic potential of CB2 receptor modulation has therefore attracted significant attention in preclinical models, underlining their protective function in the induction and maintenance of neuropathic pain. Current research involves selective CB2 agonists and the mechanisms they target, with the ultimate goal of creating safer, more efficacious treatments for neuropathic pain that avoid the risks of conventional cannabinoid and opioid therapeutics. Neuropathic pain is a disabling chronic disorder produced by nerve damage or disease, characterized by spontaneous pain, hyperalgesia (enhanced pain response), and allodynia (pain from normally non-painful stimuli). Traditional treatments, such as opioids, antidepressants, and anticonvulsants, are often unhelpful and carry great side effects, such that the identification of new analgesic mechanisms becomes an imperative.

The endocannabinoid system has become an area of interest due to its key regulatory function in pain pathways. It is composed mostly of two receptor subtypes: CB1 and CB2. CB1 receptors are expressed largely in the central nervous system and are linked to the psychotropic effects of cannabinoids, whereas CB2 receptors are expressed largely in the peripheral tissues and immune cells. It has been recently reported that CB2 receptors are upregulated in the central nervous system and dorsal root ganglia in pathological pain conditions, such as neuropathy. This adaptive reaction puts the CB2 receptor on a therapeutic interventions target for neuropathic pain. With nerve injury, a neuroimmune cascade results, with microglial and astrocyte activation in the spinal cord, enhanced release of pro-inflammatory cytokines, and both culminating in sensitization of pain. Activation of the CB2 receptor has been found to decrease this neuroinflammation, decrease activation of glial cells, and restore nociceptive transmission to normal. Preclinical models involving CB2 agonists show significant decreases in behavioural measures of pain (including mechanical allodynia and thermal hyperalgesia) across different experimental models, confirming the receptor's ability to inhibit neuropathic pain via immune modulation, without the danger of associated psychoactive effects typical of CB1-targeted interventions. In addition, genetic and pharmacological research shows that CB2 deficiency increases sensitivity to pain and neuroinflammatory reactions, whereas CB2 overexpression or activation confers robust analgesia and reduces neuropathic symptom development. Targeting the CB2 receptor for neuropathic pain, therefore, not only holds the potential for effective symptom management but also a safer profile than existing therapies. In conclusion, the cannabinoid CB2 receptor is an essential modulatory target in neuropathic pain pathophysiology. Its selective pharmacological stimulation or upregulation after nerve injury offers new pain treatment prospects, whose preclinical evidence Favors its utility in alleviating neuroimmune sensitization as well as facilitating analgesia. Further exploration of CB2 receptor modulators is estimated to meet the current unmet clinical demand for safe and effective neuropathic pain therapy.

Objectives

1. To discuss the biological function and topography of cannabinoid CB2 receptors in neuropathic pain circuits.
2. To abstract preclinical research on the effectiveness of CB2 receptor modulators in models of neuropathic pain.
3. To consider new insights into selective CB2 agonist drug discovery and mechanisms of analgesia.
4. To assess the therapeutic possibilities and challenges of CB2 receptor-directed therapies for neuropathic pain treatment.
5. To clarify the biological function and localization of CB2 receptors in neuropathic pain pathways: This includes studying the expression patterns of CB2 receptors in peripheral and central nervous system areas involved in neuropathic pain, including dorsal root ganglia, spinal cord, and immune cells, particularly under conditions of nerve injury or inflammation.
6. To assess the effectiveness of selective CB2 receptor modulators in preclinical models of neuropathic pain: This involves evaluating the

impact of CB2 agonists or antagonists on pain behaviors such as mechanical allodynia and thermal hyperalgesia in animal models caused by sciatic nerve damage, chemotherapy, or other neuropathic pain causes.

7. To characterize the mechanisms through which CB2 receptor activation affects neuroinflammation and nociceptive signaling: Examining how CB2 receptor activation affects microglial and astrocyte activation, pro-inflammatory cytokine release, and interaction between the immune system and sensory neurons that lead to pain sensitization.

8. To examine the utility of CB2 receptor modulators as safer analgesics than CB1 agonists or opioids: They are highlighted as safe pain relievers that lack psychotropic effects or addictiveness and thus emerge as good alternatives or adjuncts in pain therapy.

9. To test the possible synergistic action of CB2 receptor agonists with opioids: This involves determining if CB2 activation increases morphine-induced analgesia and diminishes tolerance and side effects, and thus enhances opioid therapy efficacy and safety.

10. To study long-term therapeutic consequences and safety profile of CB2 receptor modulation: Although a majority of data are from acute or short-term investigations, knowledge of chronic effects and potential limitations is important for clinical application.

2.METHODOLOGY:

A systematic literature review of newer research studies, reviews, and meta-analyses on CB2 receptor modulators in preclinical neuropathic pain models was performed. The databases PubMed, PMC, and ScienceDirect were searched with the keywords "CB2 receptor neuropathic pain," "CB2 agonists analgesia," and "cannabinoid receptor modulators pain." Some studies used rodent models of neuropathic pain caused by nerve damage (e.g., chronic constriction injury and sciatic nerve ligation) and chemotherapy-induced peripheral neuropathy. Information on pharmacological effects, receptor selectivity, behavioural responses, and mechanistic data was critically evaluated. The preclinical study design for research into CB2 receptor modulators in neuropathic pain includes a number of important steps, namely selection of animal models, induction of neuropathic pain, drug treatment regimens, behavioural and physiological measurements, and analysis of data methodologies.

Animal Model Selection

Rodent models (most often mice and rats) are generally employed to investigate neuropathic pain. Neuropathic pain is induced employing methodologies such as:

•Chronic constriction injury (CCI) of the sciatic nerve

•Partial sciatic nerve ligation (PSNL)

• Spinal nerve ligation (SNL)

•Chemotherapy-induced peripheral neuropathy (e.g., with agents such as vincristine).

Induction of Neuropathic Pain

Anaesthesia is used to induce standardized surgical injury to the nerves. Following baseline behavioural assessment, neuropathic pain is induced by ligation of the sciatic nerve or treatment with chemotherapeutic drugs. Monitoring post-surgery ensures adequate development of pain behaviours.

Drug Administration Protocol

CB2 receptor modulators (selective agonists or antagonists) are given by systemic injections (intraperitoneal, intravenous), local injections (intraplanar), or oral gavage. Dosage, frequency, and route of delivery are standardized for comparison. Vehicle or inactive compounds are given to negative control groups; positive controls may receive established analgesics. Genetic models with a deficit of CB2 receptors (CB2 knockout mice) are included in some studies to affirm receptor-specific effects.

Behavioural and Physiological Assays

Pivotal tests to evaluate pain behaviours and effectiveness of CB2 modulators are:

•Von Frey test (mechanical sensitivity/allodynia)

•Plantar test (thermal hyperalgesia)

•Cold plate test (cold allodynia)

•Formalin test (biphasic pain response)

These are performed at baseline (pre-induction), at frequent intervals after injury, and after drug treatment. Animals are pre-exposed to the environment of testing and each test is carried out in order for every animal.

Neurochemical and Histological Analysis

Additional studies examine tissues (spinal cord, dorsal root ganglion) further for CB2 receptor expression changes, markers of inflammation (cytokines), and glial activation by techniques like immunohistochemistry and PCR

Data Collection and Analysis

Behavioural data (withdrawal thresholds, latencies, scores) are gathered and analysed using correct statistical techniques (two-way ANOVA, post hoc tests). Intrapair comparisons between genotypes, treatment, and time points corroborate the analgesic effectiveness and mechanistic functions of CB2 modulators



Fig.no.1. Cannabinoid (CB1/CB2) Receptor-mediated pain modulation pathway

3.Recent Advancements

•CB2 receptor expression is augmented in the peripheral and central nervous system areas in neuropathic pain states, such as dorsal root ganglia and spinal cord, representing a targeted site for action.

•Selective CB2 agonists such as AM1241, JWH-133, and LY2828360 suppress allodynia and hyperalgesia in multiple models of neuropathic pain.

•CB2 activation regulates neuroimmune interactions by suppressing pro-inflammatory cytokines and glial activation, thereby reducing central sensitization.

•New CB2 agonists like itaconates and stains have been developed, and they exhibit promising analgesic activity as well as the potential for decreasing opioid dependence.

•Administration of opioids concomitantly with CB2 agonists has been found to improve pain relief, decrease opioid tolerance, and minimize side effects.

•Notably, CB2 agonists do not possess the psychoactive and addictive characteristics of CB1 receptor targeting, which enhance safety profiles.

•Design of Selective CB2 Agonists with Enhanced Profiles

New compounds have been developed recently like LY2828360, which are new CB2 receptor agonists. These exhibit highly effective analgesic activity in neuropathic pain models in animals and simultaneously suppress morphine tolerance and dependence behaviors. These drugs offer effective pain relief without the side effects related to the CNS observed with CB1 receptor agonists.

•Therapeutic Potential in Chemotherapy-Induced Neuropathy

Selective CB2 agonists have shown efficacy in preclinical models of chemotherapy-induced peripheral neuropathy (CIPN) such as paclitaxel- and vincristine-induced CIPN. This provides new avenues for treating pain associated with cancer and its treatment that are currently sub optimally managed.

•Topical Application Approaches

Experiments have indicated that local administration of CB2 agonists such as β-Caryophyllene can alleviate diabetic peripheral neuropathy through the reduction of neuroinflammation and oxidative stress, pointing towards local delivery with minimal exposure systemically as a potential approach.

•Mechanistic Insights into Neuroimmune Modulation

Improved knowledge about how activation of the CB2 receptor inhibits glial cell activation, suppresses pro-inflammatory cytokine secretion, and regulates neuronal excitability has further established the role of the receptor in regulating neuroinflammation that is core to neuropathic pain.

•Combination Therapy with Opioids

Activation of the CB2 receptor has been shown to decrease opioid tolerance and dependence development in preclinical models, validating combination therapies as a way to augment opioid analgesia while reducing side effects.

•Safety and Tolerability in Human Studies
While clinical trials with CB2 agonists like LY2828360 for osteoarthritis pain to date have not reached efficacy endpoints, they validate safety and tolerability in humans, supporting additional studies in neuropathic pain populations congruent with preclinical results.
•Pharmacotherapeutic Innovations
Emerging are novel CB2 receptor-selective compounds, such as itaconates and satins', which show favourable preclinical results, broadening the array of compounds available for addressing neuropathic pain.
•Molecular and Genetic Studies
Genetic models lacking CB2 receptors still show magnified pain and neuroinflammatory reactions, supporting CB2's physiological importance and informing the development of targeted treatments.
•Increased Models of Neuropathic Pain
Current research uses CB2 modulators in several neuropathic pain models, such as traumatic nerve injury, diabetic neuropathy, and HIV-associated neuropathy, increasing potential clinical applications

4.RESULT:

Preclinical studies consistently demonstrate that CB2 receptor modulation plays a significant role in reducing neuropathic pain behaviours in animal models. Activation of CB2 receptors—primarily located on immune cells and microglia—attenuates neuroinflammation and suppresses the release of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6.Selective CB2 agonists (e.g., JWH-133, AM1241, GW405833) have been shown to reduce mechanical allodynia and thermal hyperalgesia in models of peripheral nerve injury, chemotherapy-induced neuropathy, and diabetic neuropathy. These effects occur without the psychotropic side effects typically associated with CB1 receptor activation Conversely, CB2 antagonists or genetic deletion of CB2 receptors exacerbate neuropathic pain responses, supporting the receptor's protective role. Chronic administration of CB2 agonists also leads to sustained analgesic effects without the development of tolerance observed with opioids. Mechanistically, CB2 activation suppresses microglial activation in the spinal cord, inhibits MAPK and NF-KB signaling pathways, and promotes an anti-inflammatory phenotype in glial cells. Some studies also report modulation of peripheral immune cell infiltration and a reduction in oxidative stress markers. Overall, CB2 receptor modulators exhibit robust preclinical efficacy in attenuating neuropathic pain through both central and peripheral mechanisms, highlighting them as promising non-psychoactive therapeutic targets.

Table no.1;Preclinical evalution of CB2 receptor-targeted compound in neuropathic pain

Study / Model	CB2 Modulator	Animal Model	Outcome Measures	Main Findings	Reference
Elmes et al., 2004	AM1241 (agonist)	Chronic constriction injury (CCI) in rats	Mechanical allodynia, thermal hyperalgesia	Significant reduction in pain behaviours; effect blocked by CB2 antagonist	[Elmes et al., Br J Pharmacol, 2004]
Ibrahim et al., 2006	JWH-133 (agonist)	Spinal nerve ligation (SNL) in mice	Von Frey test, Hargreaves test	Decreased hypersensitivity; suppressed spinal microglial activation	[Ibrahim et al., Pain, 2006]
Romero-Sandoval et al., 2008	GW405833 (agonist)	Diabetic neuropathy (streptozotocin model)	Mechanical and thermal thresholds	Improved nociceptive thresholds; decreased TNF-α and IL-1β expression	[Romero-Sandoval et al., Eur J Neurosci, 2008]
Racz et al., 2008	AM630 (antagonist)	CCI model	Mechanical allodynia	Blocked the analgesic effect of CB2 agonist; no effect alone	[Racz et al., Neuropharmacology, 2008]
Deng et al., 2015	β-Caryophyllene (CB2-selective natural agonist)	Chemotherapy-induced neuropathy (paclitaxel)	Cold allodynia, thermal hyperalgesia	Reduced pain behaviours and inflammation; no tolerance developed	[Deng et al., Euri J Pharmacol, 2015]

Zhang et al., 2018	JWH-015 (agonist)	Spinal cord injury model	Mechanical allodynia, cytokine assays	Inhibited microglial activation; restored pain threshold	[Zhang et al., NeurochemInt, 2018]



Fig.No.2.Endocannabinoidsynthesis,release,and degradation at the synapse

5.DISCUSSION:

Neuropathic pain remains a therapy challenge owing to complexity and the unwanted effects of standard analgesics. Preclinical studies on the cannabinoid CB2 receptor have an advantageous analgesic profile through the modulation of inflammatory and neuronal mechanisms in neuropathic pain conditions. This receptor's selective expression in immune Neuropathic pain remains a therapeutic challenge due to complexity and the side cells and upregulation during pathological pain states make it an ideal therapeutic target to suppress neuroinflammation and hyperexcitability without the psychoactive side

effects linked to CB1 receptor activation in the CNS.

The latest developments point to the therapeutic potential of synthetic and endogenous CB2 agonists in lessening neuropathic symptoms and their synergy with opioids, possibly providing a way to reduce opioid-induced undesired effects and dependency. Nonetheless, the majority of evidence is derived from animal models; clinical translation is presently limited, partly because of pharmacokinetic issues and receptor heterogeneity. Further research is necessary to create highly selective, brain-permeable CB2 modulators and to explore long-term safety and efficacy in human subjects.

6.CONCLUSION:

Preclinical data firmly establish the therapeutic promise of cannabinoid CB2 receptor modulators for treatment of neuropathic pain through effective suppression of neuroinflammation and nociceptive sensitization without generating adverse CNS effects. These modulators offer a promising alternative or addendum to currently available pain therapies, particularly for neuropathic patients that are refractory to traditional treatment. Ongoing research and clinical trials are necessary to tap the full value of CB2-targeted therapies in treating neuropathic pain.

The preclinical conclusion for the cannabinoid CB2 receptor modulators in neuropathic pain management is that they have great therapeutic potential based on their capacity to modulate nociceptive signals and neuroinflammation without the damaging central nervous system (CNS) side effects that accompany CB1 receptor activation. Preclinical models have established that CB2 receptors are important in the modulation of neuropathic pain through immune-mediated mechanisms, specifically by regulating glial cell activation and pro-inflammatory cytokine production in response to nerve damage.

CB2 receptor-deficient mice have increased neuropathic pain behaviors and diffuse glial activation, but overexpression or activation of CB2 receptors yield decreased pain behaviors and decreased neuroinflammation. This demonstrates CB2's direct role in the inhibition of the development and maintenance of neuropathic pain conditions through the repression of central immune processes at the spinal cord level.

Selective CB2 agonists work well to reduce allodynia and hyperalgesia in various models of neuropathic pain, such as traumatic nerve injury and chemotherapy pain, strengthening their position as viable analgesic drugs. Significantly, in contrast to CB1 receptor agonists, CB2 modulators do not produce psychoactivity, addiction, or other undesirable CNS side effects, and hence are safer for the treatment of chronic pain.

Although the preclinical data are strong, clinical practice translation is also warranted by further investigation into pharmacokinetics, long-term effectiveness, and human safety. Nevertheless, CB2 receptor modulators represent an innovative mechanism-based approach to treating neuropathic pain's intricate neuroimmune pathology, possibly with treatment paradigms that are safer and more effective than the standard analgesics.

Overall, the preclinical evidence clearly confirms the cannabinoid CB2 receptor as a sound and potential candidate for the treatment of neuropathic pain, with CB2 modulators providing significant analgesia through immune modulation but without CNS side effects, making it a promising direction for future therapeutic progress.

7.REFERENCES:

1. Guindon J, et al. Cannabinoid CB2 receptors: a therapeutic target for neuropathic pain. Br J Pharmacol. 2007
2. Anthony AT, et al. Cannabinoid receptors and their association with chronic inflammatory pain. Cureus. 2020;
3. Guenther KG, et al. LY2828360, a cannabinoid CB2 agonist, suppresses neuropathic pain and reduces morphine tolerance in rats. Pharmocol Res. 2025;
4. Carey LM, et al. Peripheral sensory neuron CB2 cannabinoid receptors are analgesic in HIV-associated neuropathy. Neuropharmacology. 2023;
5. Pharmacotherapeutics role of Cannabinoid (CB1 & CB2) receptor agonists in chemotherapy-induced peripheral neuropathy: A Review. J Neonatal Surg. 2025
6. Racz IR et al., 2008 - Critical Role of the CB2 Cannabinoid Receptor in the Regulation of Central Immune Responses Leading to Neuropathic Pain. This landmark publication utilizes CB2 knockout and overexpressing mice to show CB2's contribution to modulating glial activation and neuroinflammation following nerve injury and notably influencing neuropathic pain behaviors.
7. Guindon J et al., 2007 - Illustrates that selective CB2 agonists decrease neuropathic pain behaviors in rodent models without psychoactive CB1-related side effects, pointing to CB2 as an interesting analgesic target.
8. Ibrahim MM et al., 2003 - Demonstrated that CB2 receptor agonists decrease neuropathic pain through immune modulation, yielding early pharmacological evidence for therapeutic potential.
9. Romero-Sandoval EA et al., 2008 - Established CB2-mediated suppression of microglial activation

and cytokine secretion, mechanisms responsible for the antinociceptive effects of CB2 agonists.
10. Maione S et al., 2007 - Investigated the role of endocannabinoid system modulation through FAAH inhibitors, evidencing tonic CB2 receptor activation in neuropathic pain management.
11.Klauke AL et al., 2014 - Utilized partial sciatic nerve ligation in wild-type and CB2 knockout mice to confirm the role of CB2 receptor in neuropathic pain modulation.
12.Cabral GA et al., 2008 - Discussed CB2 receptor expression in brain and spinal cord in neuropathic pain, with a focus on their contribution to central immune response.
13. Páldy E et al., 2008 - Defined new CB2 receptor agonists with slow signaling and showed their long-term anti-allodynic neuropathic pain and morphine tolerance suppression in rodents.
14. Anthony AT et al., 2020 - Evaluated CB2 receptor agonists in models of chemotherapy-induced neuropathy, validating anti-inflammatory and analgesic effects.
15. Guenther KG et al., 2025 - Outlined the efficacy of the CB2 agonist LY2828360 to diminish neuropathic pain and opioid tolerance, furthering clinical translation potential.
16. Carey LM et al., 2023 - Examined CB2 receptor activity in peripheral sensory neurons in HIV-associated neuropathy models with prominent analgesic effects.
17. Ehrhart J et al., 2005 - Showed that activation of the CB2 receptor suppresses microglial inflammatory responses.
18. Beltramo M et al., 2006 - Reported on CB2 agonists' capacity to suppress neuropathic pain symptoms without CB1-associated side effects.
19. Puffenbarger RA et al., 2000 - Documented CB2 receptor-mediated decrease in inflammatory cytokine secretion by activated microglia.
20. Klegeris A et al., 2003 - Demonstrated CB2's role in the modulation of neuroinflammation associated with pain.
21. Sheng WS et al., 2005 - Laid out the CB2 receptor agonists' inhibition of microglial activation and neuronal excitotoxicity.
22. Maione S et al., 2019 - Examined synergistic analgesic properties of CB2 agonists with opioids to diminish morphine tolerance as well as opioid side effects.
23. Romero-Sandoval EA and Eisenach JC, 2007 - Investigated analgesic processes of CB2 receptor activation in neuropathic pain, including modulation of spinal glial.
24. Van Sickle MD et al., 2005 - Characterized CB2 receptor expression within neuronal and glial cell populations within CNS.
25. Di Marzo V, 1998 - Emphasized the on-demand synthesis and regulation of endocannabinoids responsible for activation of CB2 receptors following nerve injury.
26. Agarwal N et al., 2007 - Reported elevated levels of endocannabinoids following nerve injury in peripheral and central nervous system.
27. Ofek O et al., 2006 - Demonstrated pharmacological characterization of CB2 receptor-deficient mice and their modified pain sensitivity.
28. Buckley NE et al., 2000 - Genetic research showing CB2 receptor functions in immune cell function linked to neuropathic pain.
29. Petrosino S et al., 2007 - Documented the increase of endocannabinoid concentration within brain regions linked with pain modulation.
30. Maione S et al., 2007 - Demonstrated that inhibition of FAAH increases endocannabinoid levels lowering neuropathic pain through CB2 receptors.
31. Pharmacotherapeutic reviews, 2025 - Summarized recent developments in CB2 selective agonists in chemotherapy-induced neuropathy.
32. Preclinical research demonstrating lack of central psychotropic effects with CB2 agonists (multiple authors).
33. Research describing molecular mechanisms (MAPK, cytokine modulation) through which CB2 activation suppresses neuroinflammation and pain sensitization.
34. Research on bone marrow chimera models demonstrating hematopoietic cell CB2 receptor involvement in neuropathic pain (Racz IR et al., 2008).
35. Reviews of CB2 receptor agonists' safety profile and suitability for chronic pain therapy without addictive liability.